Review the ECLIPSE study published in New England Journal of Medicine.  See the data

Patients who are not up to date with screening
are at increased risk of CRC mortality1

Did you know?

Over 75% of people who died from CRC
were not up to date with screening1

CRC remains the second-leading
cause of cancer-related deaths in
the United States.2

CRC screening can drastically increase survival outcomes when detected early2



Early Stage
Late Stage
Sadly, low screening compliance may contribute to over half of patients
getting diagnosed after their disease has spread.2,3

CRC screening compliance rates remain stagnant and low with current stool tests and colonoscopy4

Many factors can prevent patient follow-through for more conventional methods5-8

  Stool tests Colonoscopy
Stool tests
  • Disgust with handling stool
  • Hassle to complete
  • Apprehension about accurately completing a test at home
Compliance rate
  • Discomfort
  • Fear of an invasive procedure
  • Time commitment (prep to procedure can be 1-3 days)
Compliance rate
14-67%9-11 38-50%6,11
Shield is a blood test that is easy to complete12

High compliance rate in real world clinical settings

Test tube with blood.

Sign up to receive the latest updates on ShieldTM

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.

*Compliance rate for the first 20,000 patients who were prescribed Shield.13
Shield™ is a qualitative laboratory developed test intended to detect colorectal cancer by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
  • The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
  • Patients with an “abnormal signal detected” Shield result should be referred for colonoscopic evaluation
  • A “normal signal detected” Shield result does not preclude the presence of colorectal cancer, and patients should continue participating in guideline-recommended screening programs
  • Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
References 1. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156(1):63-74. doi:10.1053/j.gastro.2018.09.040 2. National Cancer Institute. Colon and rectum stage distribution of SEER incidence cases, 2009-2018. Accessed March 18, 2024. 3. Andrew AS, Parker S, Anderson JC, et al. Risk factors for diagnosis of colorectal cancer at a late stage: a population-based study. J Gen Intern Med. 2018;33(12):2100-2105. doi:10.1007/s11606-018-4648-7 4. Health and economic benefits of colorectal cancer interventions. Centers for Disease Control and Prevention. Updated December 21, 2022. Accessed March 1, 2024. 5. Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Commun. 2017;10:27-31. doi:10.1016/j.ctarc.2016.12.004 6. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20(11):989-995. doi:10.1111/j.1525-1497.2005.00164.x 7. Parks P. Innovation in colorectal cancer screening - there has to be a better way. Am J Manag Care. Published October 9, 2017. Accessed September 17, 2021. 8. American Society of Clinical Oncology. Colonoscopy. website. Updated December 2019. Accessed December 7, 2021. 9. Gellad ZF, Stechuchak KM, Fisher DA, et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol. 2011;106(6):1125-1134. doi:10.1038/ajg.2011.11 10. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-582. doi:10.1001/archinternmed.2012.332 11. Exact Sciences. Third quarter 2019 webcast and conference call. Updated October 29, 2019. Accessed December 17, 2021. https:/ 12. Chung DC, Gray DM II, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973-983. doi:10.1056/NEJMoa2304714 13. Data on file. Guardant Health, Inc.